Text Size

Neuroimaging Studies of Depression in Parkinson's Disease

This study has been completed.
Sponsor:
Collaborators:
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
Lee Blonder, University of Kentucky
ClinicalTrials.gov Identifier:
NCT00518258
First received: August 16, 2007
Last updated: May 16, 2013
Last verified: April 2013
History of Changes
  Purpose

The purpose of this study is to investigate similarities and differences in the neural pathways of depressed Parkinson's patients, non-depressed Parkinson's patients, and healthy controls using magnetic resonance imaging (MRI) of the brain and neuropsychological assessment.


Condition
Parkinson's Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Neuroimaging Studies of Depression in Parkinson's Disease

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Kentucky:

Estimated Enrollment: 120
Study Start Date: July 2006
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Patient Group
2
Control Group

Detailed Description:

Depression is a common and potentially serious complication of Parkinson's disease (PD). Studies show that approximately 40 percent of PD patients are depressed. There is evidence that these patients have deficits in neuropsychological function relative to non-depressed PD patients. Despite the widespread toll on emotional health posed by PD, few studies have undertaken a comprehensive examination of the neural underpinnings of Parkinsonian depression. In this project, we will compare depressed versus non-depressed Parkinson patients to a sample of demographically-matched healthy controls using neuropsychological assessment and magnetic resonance imaging (MRI). To investigate possible effects of anti-Parkinsonian medication on mood, cognitive function, and neural response, PD patients will be tested both off and on Parkinsonian medications.

  Eligibility

Ages Eligible for Study:   40 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Neurology clinics, community sample

Criteria

Inclusion Criteria:

  • right-handed
  • willing/able to undergo magnetic resonance imaging (MRI)

Exclusion Criteria:

  • history of neurological condition other than Parkinson's disease
  • history of psychiatric condition other than depression
  • history of substance abuse/dependence
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00518258

Locations
United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40536
Sponsors and Collaborators
Lee Blonder
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
Principal Investigator: Lee X. Blonder, PhD University of Kentucky
  More Information

Additional Information:
Click here for more information about this study.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Lee Blonder, PI, University of Kentucky
ClinicalTrials.gov Identifier: NCT00518258     History of Changes
Other Study ID Numbers: R01-MH78228-2
Study First Received: August 16, 2007
Last Updated: May 16, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Kentucky:
Parkinson's Disease
Magnetic Resonance Imaging (MRI)
neuropsychological assessment

Additional relevant MeSH terms:
Depression
Depressive Disorder
Parkinson Disease
Behavioral Symptoms
Mood Disorders
Mental Disorders
Parkinsonian Disorders
 Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on May 23, 2013